Listened to 4 hours of the NIH meeting to discuss upcoming initiative for clinical trials for #longcovid.
Some themes
- Several people advocated small, fast trials to ID subsets who benefit from drugs & find meaningful clinical endpoints.
Viral persistence, immune dysfunction & microclots all offer targets for treatment but not every patient shows each feature; makes trial design tricky and requires work to ID eligible patients.
- Big PhRMA still largely on the sidelines
Brian Vastag /
npub1c6…v4fy5
2024-09-23 22:42:19
Author Public Key
npub1c6dr99s0tdv8v94pz7p7f29wae0ck8sx0lj2zmc9r98l8uhlzfcsrv4fy5Published at
2024-09-23 22:42:19Event JSON
{
"id": "0a0ea37242afa70965a947df087c676ffd55381affb51a3a99dee20f92acf40f",
"pubkey": "c69a32960f5b587616a11783e4a8aeee5f8b1e067fe4a16f05194ff3f2ff1271",
"created_at": 1727131339,
"kind": 1,
"tags": [
[
"t",
"LongCovid"
],
[
"proxy",
"https://sciencemastodon.com/users/brianvastag/statuses/113189279472031922",
"activitypub"
]
],
"content": "Listened to 4 hours of the NIH meeting to discuss upcoming initiative for clinical trials for #longcovid.\n\nSome themes\n- Several people advocated small, fast trials to ID subsets who benefit from drugs \u0026 find meaningful clinical endpoints.\n\nViral persistence, immune dysfunction \u0026 microclots all offer targets for treatment but not every patient shows each feature; makes trial design tricky and requires work to ID eligible patients.\n\n- Big PhRMA still largely on the sidelines",
"sig": "22671da76bdc600a72c58bd65fb3c60a1b6114ed91708ee37af0fc3e4b214aed83f75b8690dcc048ef57147c2cbd3f098aaaa284ad50833a5d458f1a0b3f1f84"
}